Current stock page

Stock Analysis

Palvella Therapeutics, Inc. (PVLA) Stock Analysis

Palvella Therapeutics, Inc. (PVLA) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

PVLA Stock Analysis Summary

Palvella Therapeutics, Inc. (PVLA) currently has an AIQ Score of 70/100, indicating a bullish setup. Momentum is the strongest factor at 84/100. Risk is the weakest current factor at 47/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

PVLA at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$152.48
AIQ Score70/100
Overall ViewBullish
Technical Analysis ConsensusBuy
Market Cap$2.22B
P/E Ratio (TTM)-27.72
Forward P/E—
EPS (Q3 FY2026)-$1.70
Revenue (Q3 FY2026)$0
Dividend Yield (TTM)0.00%
Beta1.65
Volume241.73K
52-week range$72.23-$179.95
RSI 1452.57
50-Day SMA$143.56
200-Day SMA$130.44
Analyst Price Target$237.33
Next Earnings—
As of Nov 13, 2026 · Market close

PVLAPalvella Therapeutics, Inc.

Healthcare / Biotechnology

Leader

Sector Leader

BullishEdge 10/10
$152.48−$0.70 (−0.46%)

Latest quote

  • Momentum
    84
  • Value
    —
  • Quality
    65
  • Risk resilience
    47
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

PVLA Stock Analysis Summary

Palvella Therapeutics, Inc. (PVLA) currently has an AIQ Score of 70/100, indicating a bullish setup. Momentum is the strongest factor at 84/100. Risk resilience is the weakest current factor at 47/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bullish

In a bullish regime, PVLA has AIQ Score of 70/100 with Momentum base of 84/100 and fading Risk resilience at 47/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Momentum (84/100) leads while Risk resilience (47/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · -0.46% stock move · PVLA classified in Biotechnology.

Current Evidence

BullishPVLA is in a bullish AIQ regime; Momentum is the strongest visible factor at 84/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is PVLA Bullish or Bearish Right Now?

PVLA currently has a bullish overall setup. Momentum is the strongest factor at 84/100, while Risk Resilience is weakest at 47/100. The current evidence suggests a constructive setup.

Bull Case
  • - Quality is supportive at 65/100.
  • - Momentum is constructive at 84/100.
  • - Price is +6.22% above its 50-day SMA.
  • - Analyst target implies +55.65% upside from the latest quote.
  • - Technical consensus has more buy votes than sell votes (29 vs 10).
Bear Case
  • - Risk Resilience is weak at 47/100.

Current Consensus

PVLA's Technical Analysis Consensus is currently Buy, with 29 buy, 7 neutral, and 10 sell votes. PVLA's 14-day RSI is 52.57, which places the stock in a neutral momentum range. PVLA's beta is 1.65, indicating greater market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in PVLA?

The largest recent change in PVLA is Momentum moving up by 5.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
+2.0
Momentum
+5.0
Quality
+0.0
Risk
+1.0

What Would Change the PVLA Outlook?

The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

PVLA Decision Framework

Public evidence layers, setup checks, and risk context for Palvella Therapeutics, Inc..

Palvella Therapeutics, Inc. (PVLA) Stock Analysis

Palvella Therapeutics, Inc. has an AIQ Score of 70/100 in a Bullish regime. Momentum is strongest at 84/100. Beta is 1.65, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextPVLA is in a Bullish AIQ regime with score 70/100.
Signal ConflictThe primary conflict is that momentum leads at 84/100 while risk lags at 47/100.
Factor EvidenceMomentum 84/100 · Quality 65/100 · Risk 47/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Momentum is the strongest factor at 84/100.

TimingPass

Momentum is 84/100 and RSI (14) is 52.6.

Regime fitPass

PVLA is in a Bullish regime at 70/100.

Risk controlFail

Risk factor is 47/100 with beta 1.65 and annual volatility 84.47%.

ConflictWait

Current conflict: momentum leads at 84/100 while risk lags at 47/100.

AIQ Score
70/100
Price
$152.48
Beta
1.65
RSI (14)
52.6

PVLA Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

PVLA Fundamentals

PVLA valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$0
Net income
-$24.64M
Free cash flow
-$14.43M
View full PVLA fundamental analysis

PVLA Technical Analysis

PVLA technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Buy
RSI 14
52.57
Price vs SMA-50
+6.22%
View full PVLA technical analysis

PVLA Stock Catalysts

Track PVLA earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
—
Analyst target
$237.33
News items
0
View PVLA earnings and stock catalysts

PVLA Dividend Analysis

PVLA dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View PVLA dividend history and analysis

PVLA Financial Data

PVLA revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$0
EPS
-$1.70
Periods
8
View PVLA financials

PVLA Risk Analysis

PVLA volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.65
Risk score
47/100
1Y volatility
84.47%
View PVLA risk analysis

PVLA Stock News

PVLA stock news, market tone, recent headlines, and catalyst context.

News items
0
Updated
—
Sentiment
—
Read PVLA stock news

PVLA vs Biotechnology Peers

Current peer cohort: PVLA · QURE · RAPP · RCUS · REPL. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
PVLA
Current stock
70/100—84/10047/1001.1284.47%Current
QURE
uniQure N.V.
39/10038/10041/10031/1000.39132.25%PVLA vs QURE
RAPP
Rapport Therapeutics, Inc. Common Stock
43/10042/10033/10039/1000.3562.34%PVLA vs RAPP
RCUS
Arcus Biosciences, Inc.
39/10043/10034/10042/1000.0562.65%PVLA vs RCUS
REPL
Replimune Group, Inc.
60/100—97/10026/1001.3187.93%PVLA vs REPL
Pairwise Compare links: QURE · RAPP · RCUS · REPLPVLA vs QUREPVLA vs RAPPPVLA vs RCUSPVLA vs REPLCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a PVLA stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for PVLA: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-27.72
As of Nov 13, 2026
Revenue growth
—
Gross margin
0.00%
Current debt / equity
0
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$0
Quarter net income
-$24.64M
Quarter free cash flow
-$14.43M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bullish
Momentum
Mixed
RSI 14
52.57
MACD
6.84

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
47/100
Beta
1.65
Annual volatility
84.47%
Max drawdown
-31.11%

PVLA Stock FAQ

What is PVLA stock price today?

Palvella Therapeutics, Inc.'s current stock price is $152.48. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is PVLA bullish or bearish right now?

PVLA's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is PVLA's market cap?

PVLA's market cap is $2.22B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is PVLA's current P/E ratio?

PVLA's current P/E ratio is -27.72 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is PVLA's RSI?

PVLA's 14-day RSI is 52.57 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is PVLA above its 50-day and 200-day moving averages?

PVLA is 6.22% from its 50-day SMA and 16.90% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is PVLA's next earnings date?

PVLA's next earnings date is a key event to check before making a decision. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does PVLA pay a dividend?

PVLA's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.